Thursday, July 31, 2008

Stomach bug treatment for cancer

Stomach bug treatment for cancer

Eradicating a common bug in people with stomach cancer can prevent the disease from recurring, research suggests.

Helicobacter pylori, proved to be the cause of most stomach ulcers, has also been linked with stomach cancer.

In a study of 550 people who had stomach cancer surgery, antibiotics which killed the bug cut the risk of a second cancer developing by two-thirds.

There will now be a trial of 56,000 British people to see if killing the bacterium stops the cancer developing.

H. pylori lives in the stomach, and accounts for up to 90% of duodenal ulcers and up to 80% of gastric ulcers.


Preventing gastric cancer by eradicating H. pylori in high-risk regions should be a priority
Dr Nicholas Talley

It was famously linked with stomach ulcers by two Australian researchers - one of whom deliberately infected himself to prove the theory - who were awarded the Nobel prize for their discovery in 2005.

The World Health Organisation also classes the bacterium as a leading cause of stomach cancer.

Prevention

Previous trials on eradicating H. pylori as a method of preventing further stomach cancers in patients who have undergone surgery have been conflicting.

But the latest study, done in Japan, found that the strategy could be very useful.

Patients with early stomach cancer underwent a procedure to remove the cancerous cells and surrounding tissue.

Half of them were then treated with a course of drugs designed to eradicate H. pylori - lansoprazole, amoxicillin and clarithromycin - and half received dummy pills and were then examined at six, 12, 24 and 36 months to see if the cancer had reappeared in a different site.

After three years, a second stomach cancer had developed in nine patients in the eradication group compared with 24 in the control group.

Overall, the risk of developing cancer was reduced by 65% with H. pylori treatment.

Study leader Dr Mototsugu Kato, from Hokkaido University Graduate School of Medicine said: "We believe that our data add to those from previous studies showing a causal relationship between H. pylori infection and gastric cancer, and also support the use of H. pylori eradication to prevent the development of gastric cancer."

Writing in the same issue of The Lancet, Dr Nicholas Talley, of Mayo Clinic Jacksonville, Florida, US said: "Preventing gastric cancer by eradicating H. pylori in high-risk regions should be a priority."

Henry Scowcroft, science information manager at Cancer Research UK, said: "This result adds to our understanding of the relationship between H pylori and stomach cancer, and to the debate on how we should treat people with this infection.

He added the charity was helping to fund a study to assess whether elimination of the bacteria could prevent cancer developing.

"The trial aims to recruit 56,000 people across the UK, treat any who show signs of H pylori infection, and follow them over 15 to 20 years to see if this treatment is effective."

Exercise pills 'increase stamina'

Exercise pills 'increase stamina'

Scientists are moving closer to developing a pill which could deliver some of the benefits of exercise - even to sedentary people - a study suggests.

The journal Cell reports US researchers now have two possible pills which appear to be able to build muscle, increase stamina, and even burn fat.

In tests, mice were able to run 44% further - suggesting humans may be able to do the same without prior training.

The concept is controversial because of fears they could be misused in sport.


If you like exercise, you like the idea of getting 'more bang for your buck'
Professor Ronald Evans
Howard Hughes Medical Institute

With this in mind, lead researcher Professor Ronald Evans, from the Howard Hughes Medical Institute, and the Salk Institute in California, has produced a test which will allow the drugs to be detected in the urine and blood of competitors.

He says the drugs could eventually help tackle muscle wasting diseases, or help improve the health benefits of exercise in people at risk of conditions such as diabetes.

Instant endurance

The two drugs, labelled AICAR and GW1516, appear to have an effect on a gene involved in the building and regulation of muscle.

This "master gene" - PPAR-delta - has the ability to control the activity of many other genes - so adjusting it could in theory have a widespread effect on the way the body works.

Genetically altering mice to enhance the activity of the gene led to the development of muscle which was much more likely to burn fat than burn sugar.

It also made "marathon mice" who were able to run much further on a treadmill.

The next step was to produce similar effects using a drug rather than a genetic alteration.

The first version, a pill called GW1516, again produced the "fat burning" effect, but no change on exercise performance until the team started training the mice with long treadmill sessions.

At the end of a series of these, the mice given the drug were running 77% longer than those training without its benefits.

The latest drug, AICAR, goes one step further, finding a different way to act on the same muscle cell mechanism.

This time the mice did not need to train - after just four weeks on the drug, they ran 44% further on their treadmills without any prior exercise.

Exercise results

Both versions could one day serve a purpose in humans, said Professor Evans.

"If you like exercise, you like the idea of getting 'more bang for your buck'," he said.

"If you don't like exercise, you love the idea of getting the benefits from a pill," he said.

He said the most obvious potential use was in conditions, such as diabetes, where exercise was a proven benefit.

"Almost no-one gets the recommended 40 minutes to an hour per day of exercise - for these people, if there was a way to mimic exercise, it would make the quality of exercise they do more efficient."

However, Colin Palmer, a professor of pharmacogenetics at the University of Dundee, said that the idea of the drug had proved controversial.

"It's basically a drug that enhances training. The thing that raises eyebrows is the concept of a drug that improves endurance training for sports professionals."

Sunday, July 27, 2008

Weathering the Storm

The specter of global stagflation looms, but in Brazil, things couldn't be better. How a socialist giant became the world's hottest market.

Mac Margolis
NEWSWEEK
Updated: 11:23 AM ET Jul 26, 2008

The specter of rising food and fuel prices now threatens to destroy an era of unprecedented global prosperity, with two notable exceptions: Brazil and Canada. Both countries produce and export enough food and fuel not just to offset the worst of global inflationary pressures but even to turn the price spike from a menace to a boon. They are the only two major economies where prices have not burst the upper limit of the central bank's inflation target. And of the two, Brazil is by far the more surprising success story. The country that suffered the longest and perhaps the most debilitating bout of hyperinflation in recent history is now a rare island of relative stability and prosperity. Brazil's inflation is running at 6.5 percent, a rate that worries the country's money minders but thanks to their zeal is still the lowest level in all the major emerging markets.

Luck has helped. Brazil is blessed with vast resources, including timber, fresh water, gold and the world's largest cache of iron ore. Farms stretch from horizon to horizon, and while most of the world is running out of arable land, Brazil has more than 70 million hectares still to plow. Plumbing deep water reserves, the country has announced massive oil finds that may total 30 billion barrels, the largest discovery in the Western Hemisphere in three decades. For Brazilians, who once joked that "Brazil is the land of the future, and always will be," this good fortune is a serious shock. "Brazil has had interesting moments before, but this is extraordinary," says Otávio Vieira, executive director of private banking at the Swiss-owned Banco Safdie, who has seen his portfolio swell by 150 percent since 2006.

Although raw materials and semifinished goods still kick in two thirds of Brazil's export revenues, few nations have done as much to develop their natural bounty, whether in mining, energy or agriculture. Brazil has nearly doubled grain production in the last decade and is the only country producing cost-efficient biofuels without beggaring its food larder.

Better yet, the economy has accelerated without overheating. There are other major emerging markets that are growing faster, but India and Russia both have double-digit inflation while China is just shy of that dangerous threshold. No emerging nation has moved earlier or more intelligently than Brazil to head off the cancer of inflation, as evidenced last week when the Central Bank raised the benchmark lending rate for the third time this year.

This comes after a half century of colossal mistakes. The postwar economy surged and plunged so wildly that Brazilians came to call their business cycle o vôo da galinha ("the flight of a chicken"). Before the Plano Real, the economic-stabilization reform of 1994, Brazilians weathered 15 straight years of three-digit inflation—"the longest period of hyperinflation in the modern history," says Central Bank president Henrique Meirelles. Time and again, instead of solid reform, the government responded with ill-advised fix-it plans and price freezes that led only to massive shortages, strikes, riots and new bouts of hyperinflation that rendered the national currency worthless. The detritus is in display cases at the Brazilian mint outside Rio: cruzeiros, new cruzeiros, cruzados, cruzados novos, cruzeiros reaisall emblazoned with national heroes or fauna and flora, each note handsomer than the last. All forgotten now.

By 2001, Brazil's economy was stable but practically dormant. That year Jim O'Neill, the chief economist for Goldman Sachs, coined the term BRICs to describe Brazil, Russia, India and China—the emerging markets he expected to drive the international economy by midcentury. People laughed at the inclusion of Brazil. "I was told that I must have put the B in BRICs to make the acronym sound better," recalls O'Neill.

By 2002, Brazil seemed headed for yet another crisis. The economy was flat, prices were surging and a hirsute former union man with surly words for the free market was poised to take office. But Luiz Inácio Lula da Silva artfully dissembled, playing to the gallery of his companheiros in the leftist Workers' Party, but also quietly breaking bread with business executives, foreign investors and lenders. Lula is not a maverick; he halted the privatizations that were the hallmark of the previous administration and despite his fabulous popularity ratings has failed to advance a single major reform—whether of the loss-making pension system or the corruption-addled political-party structure. He actually increased the already smothering tax burden, from 34 to 36 percent of the GDP, higher than any other remerging market.

But from the beginning he has held a steady middle course, becoming the unlikely paladin of economic stability. He appointed Meirelles, a BankBoston executive, to head the Central Bank and he forced the bureaucrats to slash spending and to build surpluses year after year; in June, he upped the target again from 3.8 to 4.8 percent of GDP. Against howls of protests from the left, industry and his own vice president, he also backed the bitter medicine of the Central Bank. As many developing nations flail at inflation by hoarding food and mandating price freezes, Brazil pre-empted the global food and energy spike by raising the benchmark-lending rate three times this year to 13 percent, one of the highest in the world.

Brazil's commitment to fight inflation signals an end to a history of false starts. In the 1950s, when bossa nova was on the world's Victrola, the ambitious civilian President Juscelino Kubitschek laid out a rosary of huge public works to make the nation grow "50 years in five." (Brazil boomed; so did prices.) In the early 1970s, the Brazilian miracle saw GDP grow by double digits under the marching orders of military leaders, which set the stage for hyperinflation. "Fifteen years ago, there used to be great debate about what to do," says Albert Fishlow, a Brazil scholar at Columbia University. "Today 90 percent of economists basically agree, and people sit down and talk about strategies for development instead of searching for miracles."

Brazil's new consensus marks the end of five centuries of state rule over the economy, and the emergence of a new private market economy. In 2007, Brazil hosted a record 75 initial public stock offerings, trailing only China, as companies including ethanol distillers and tech start-ups raised rivers of cash. The stock exchange itself, known as Bovespa BM&F, went public last October, raising $3.7 billion, one of the biggest initial public offerings of 2007. Now the São Paulo stock market has eclipsed the giant state development bank BNDES as a source of cash for new businesses—a telling symbol of a country still molting from command and control to a market democracy.

Rising market competition acts as a defense against the return of inflation. This onetime drowsy rural nation now has one of the most diversified economies in the developing world, exporting iron ore, steel and soybeans, but also small commercial jets, banking services, custom-made buses, fine paper and equipment for air conditioners. Three years ago, Embraer overtook Canada's Bombardier to become the world's largest maker of midsize commercial jets. Now Brazilian-Belgian InBev is poised to become the world's largest brewer after closing a deal to buy the American giant Anheuser-Busch in mid-July. The globalizing economy has helped drive up productivity growth, to more than 3 percent a year since 2002 and now accelerating. And productivity growth is what allows a nation to make more profits—without raising prices. Brazil is now the world's leading exporter not just of coffee but soybeans, beef, sugar cane, ethanol and frozen chickens.

Caging the inflation threat has also won Brazil a new standing in the financial markets. Fitch Ratings and Standard & Poor's recently elevated Brazil's debt from junk to investment grade. Brazil's foreign reserves have risen from $16 billion in 2002 to more than $200 billion. The Brazilian real has climbed 20 percent against the dollar in the past 12 months, outperforming all of the world's most-traded currencies. Brazil attracted $35 billion in foreign direct investment in 2007, doubling the figure from the year before, and is set to pull in more foreign direct investment than all nations but China in 2008. "We are giving Brazil one of our best weightings," says Mark Mobius, head of Templeton Management Fund, with $5 billion in Brazil. "Brazil is in a good position moving forward."

Brazil's reputation has shifted so completely, many analysts now find favorable ways to compare Brazil with the other BRICs. While the booms in China and India are driven by poor peasants fleeing farms for factories in the city, Brazil's demographic revolution started decades ago; 85 percent of the country's 190 million people now live in cities. The result is potentially less dynamic, but already richer and more stable. The per capita income of $8,450 is far higher than in India ($1,100) or China ($3,000). Russia, with more than $12,000 per capita, is richer, but that is due almost entirely to the recent oil boom. Brazil is also the only BRIC country with both an established democracy (like India) and no rebel province equivalent to a Chechnya, Kashmir or Tibet. "In Brazil, progress is steady but slow," says economist Marcelo Neri, at the Getúlio Vargas Foundation, a leading business school. "It's like the fable of La Fontaine about the worker ant versus the noisy cicada. This is more a country of ants than of cicadas."

Brazil is still on the mend. Red tape, crumbling infrastructure, a chaotic public-health system and widespread illiteracy all threaten Brazil's competitiveness. With his rock-star ratings, Lula still has the clout to push the reforms the country needs. Until now, with the wind at Brazil's back, he hasn't had to bother. But banking on luck instead of reform is no business plan in the global economy. For Brazil it could be the difference between finally taking off and merely flapping in the wind.

Tuesday, July 22, 2008

Drug for deadly prostate cancer

By Richard Warry
Health editor, BBC News website

Scientists are hailing a new drug to treat aggressive prostate cancer as potentially the most significant advance in the field for 70 years.

Abiraterone could potentially treat up to 80% of patients with a deadly form of the disease resistant to currently available chemotherapy, they say.

The drug works by blocking the hormones which fuel the cancer.

The Institute of Cancer Research hopes a simple pill form will be available in two to three years.

Please turn on JavaScript. Media requires JavaScript to play.

Richard Pflaum talks about his trial of Abiraterone

An advanced clinical trial involving 1,200 patients around the world is currently under way, with more trials likely later this year.

Prostate cancer is the most common cancer among men.

It is estimated that up to 10,000 men a year in the UK are diagnosed with the most aggressive - and almost always lethal - form of prostate cancer.

Typical life expectancy following chemotherapy is no more than 18 months.

It had been assumed that the cancer was driven by sex hormones such as testosterone produced in the testicles.

Current treatments work by stopping the testicles from producing testosterone.

New action

However, experts have now discovered that the cancer can feed on sex hormones from all sources, including supplies of the hormone produced by the tumour itself.


The changes in my life have been dramatic
Simon Bush
Cancer trial patient

Abiraterone works by blocking production of the hormones throughout the body.

The latest study, published in the Journal of Clinical Oncology, is based on just 21 patients with advanced, aggressive prostate cancer treated with the drug - but data has been collected on a total of 250 worldwide.

It found significant tumour shrinkage, and a drop in tell-tale levels of a key protein produced by the cancer called prostate specific antigen in the majority of patients.

Many of the patients have reported a significant improvement in the quality of their lives.

Some were able to stop taking morphine for the relief of pain caused by the spread of the disease to their bones.

Real hope

Lead researcher Dr Johann de Bono said the findings needed to be confirmed in larger trials.


We believe we have made a major step forward in the treatment of end-stage prostate cancer patients
Dr Johann de Bono
Institute of Cancer Research

At this stage, no patient has taken the drug for longer than two-and-a-half years, and so it has not been possible to determine exactly what the effect of the drug on life expectancy will be.

But he said: "We believe we have made a major step forward in the treatment of end-stage prostate cancer patients.

"These men have very aggressive prostate cancer which is exceptionally difficult to treat and almost always proves to be fatal.

"We hope that abiraterone will eventually offer them real hope of an effective way of managing their condition and prolonging their lives."

It is hoped the drug will also aid other cancer patients, including those with breast cancer.

Professor David Webb, an expert in clinical pharmacology at the University of Edinburgh, said: "This agent clearly looks promising, but it is still at the early stages of clinical development.


FROM THE TODAY PROGRAMME

Please turn on JavaScript. Media requires JavaScript to play.

"It will be crucial to look carefully at the balance between its benefits and harms, before drawing firm conclusions about the usefulness of this new drug.

"Important side effects often only emerge with the larger clinical studies that now need to be done."

John Neate, of The Prostate Cancer Charity, said: "This is an exciting development which has been eagerly anticipated."

Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/7502238.stm

Published: 2008/07/22 08:01:16 GMT

© BBC MMVIII

Wednesday, July 16, 2008

Experts are developing a flexible surgical robot, known as the i-Snake, which they say could revolutionise keyhole surgery

i-Snake 'will transform surgery'
i-Snake
The i-Snake is highly flexible
 

It could enable surgeons to do complex procedures previously possible only through more invasive techniques.

A team at Imperial College London has been granted £2.1 million for the work.

They envisage using the i-Snake - a long tube housing special motors, sensors and imaging tools - for heart bypass surgery.

But it could also be used to diagnose problems in the gut and bowel by acting as the surgeon's hands and eyes in hard to reach places inside the body.

The Imperial College team, which includes health minister and surgeon Lord Ara Darzi, will test the device initially in the laboratory before it is used on patients.

KEYHOLE SURGERY MILESTONES
1900s - Mirrors, lights and lenses attached to endoscopic tubes are used to examine bodies' interiors
1930s - Fibre-optics offer an essential light source; endoscopes now thinner and more flexible
1970s - Cameras attached to endoscopes mean that surgeons can operate from images on a screen. Lasers developed which can perform surgery
Source: Ghislaine Lawrence, Science Museum, London

Minimally invasive surgery has obvious advantages - it can mean smaller scars, reduced hospital stays and shorter recovery times.

Surgeons are also looking at ways to avoid skin incisions altogether.

One approach is Natural Orifice Transluminal Endoscopic Surgery or Notes. This means operating in the peritoneal space through natural orifices or cavities, such as the bowel.

Lord Darzi said: "The unrivalled imaging and sensing capabilities coupled with the accessibility and sensitivity of i-Snake will enable more complex diagnostic and therapeutic procedures than are currently possible.

"The cost benefits that i-Snake will introduce include earlier, cheaper and less invasive treatment, faster recovery and procedure times and intangible benefits through an increase in patient care and quality of life."

Dr Ted Bianco, director of technology transfer at the Wellcome Trust, said: "Gone are the days when the surgeon's knife ruled in the operating theatre. The future of surgery is in smart devices like i-Snake."

Vintage future seen for Chinese wine


By Gavin Stamp
Business reporter, BBC News

China is set to become the world's largest producer of bulk wine in 50 years time as well as a major force in fine wine, experts are forecasting.

Chinese wine currently has a low profile outside of Asia even though, in terms of number of vineyards, it is already the world's fourth-largest player.

But this is all set to change, say wine merchants Berry Brothers & Rudd, as increased investment and technical expertise, allied to favourable soil conditions, transform its reputation for excellence.

This is one of the more startling predictions contained in Berry's analysis of the future of viticulture in the first half of the century.

Its experts believe global warming will cause a "radical shake-up" of the industry.

Eastern promise

Certain countries, most notably Australia, may no longer be able to grow wine in bulk quantities by 2058 because of a lack of water.

In contrast, it sees India and large parts of eastern Europe - as well as China - emerging as new forces in the industry.

"China has the vineyards but not the technical expertise," says Alun Griffiths, Berry's wine director, of its current status.

But he believes it won't be long before it is producing high quality Cabernets and Chardonnays, and will eventually produce fine wine to "rival the best of Bordeaux".


In 50 years, consumers will ask for wine by the brand name or flavour and won't know, or care, where it has come from
Jasper Morris, Berry Brothers & Rudd

The number of Chinese wineries will increase 10-fold from current levels of about 400, while new areas will be discovered with the right climate to produce fine wine.

"If good people from wine producing countries think there is an opportunity to make wine in China, they will go there and invest," Mr Griffiths adds.

The global wine map could look very different in 2058, Berry believes.

Production in Australia may be "marginalised" into wetter, cooler areas such as Tasmania and the likes of Canada, Poland and Slovenia may feature more prominently.

Fans of English wine will be encouraged to hear that Berry predicts a bright future with the amount of land cultivating wine potentially rivalling that of France by 2058.

If English sparkling wine gets more support from drinkers and has sufficient critical mass to bring prices down, it might one day be able to compete with champagne.

Farewell bottles?

Should other Berry predictions come to pass by 2058, the wine bottle will become virtually obsolete - replaced by plastic or reinforced cardboard containers.

Only a tiny fraction of wine will continue to be corked, Berry believes, with screw caps becoming the norm across the industry.

Other innovations will see chips being embedded into containers to prevent counterfeiting and the introduction of genetically modified grapes and yeast to improve fermentation and reduce alcohol levels.

However, the most radical change may occur in how wine is labelled and marketed.

Country and grape-specific derivations such as Shiraz or Merlot could disappear in favour of brand-oriented versions as spirits producers and supermarkets become major wine owners in their own right.

"In 50 years, consumers will ask for wine by the brand name or flavour and won't know, or care, where it has come from," says Jasper Morris, responsible for buying Berry's Burgundy wines.

Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/business/7498334.stm

Published: 2008/07/13 15:54:00 GMT

© BBC MMVIII

Wednesday, July 2, 2008

Cold sore virus secret revealed


The secret of how the cold sore virus manages to persist for a lifetime in the human body may have been cracked by US scientists.

The herpes simplex virus 1 (HSV-1) can lie dormant in facial nerves, emerging periodically to cause sores.

A Duke University Medical Center team may have uncovered how it can reactivate itself from a dormant state.

The finding, published in the journal Nature, could eventually lead to new treatments.


It's quite likely that over the next few years we will find a lot of viruses, such as HIV, have these small RNAs during latency
Dr Stacey Efstathiou
Cambridge University

When fighting a virus, the immune system relies heavily on the protein chemicals produced by the virus which it uses to help mark it for destruction.

Herpes viruses manage to evade the immune system by shutting down production of these proteins completely, and remaining in this state for long periods before starting to replicate again.

This is why patients, once infected, have occasional flare-ups of cold sores or genital herpes, and can never get rid of the infection completely.

However, there is one thing that HSV-1 does produce, the precise role of which has puzzled scientists for some years.

It is a type of RNA, a single strand of genetic information copied from the DNA of the virus. In other viruses, these RNAs make proteins that are useful to the virus, but in herpes, this was not the case.

The Duke University team suspected that it somehow helped keep the virus in its dormant state, and studied what happened to these "latent RNAs" in mice.

They found they were broken down into even smaller strands, called microRNAs, and these appeared to block the production of proteins which reactivated the virus.

Effectively, they were helping keep the virus in its dormant state.

Wake-up call

Professor Bryan Cullen, who led the research, said: "We have provided a molecular understanding of how HSV-1 hides and then switches back and forth between the latent and active phases."

He said a drug based on blocking these microRNAs could in theory "wake up" all the viruses, making them vulnerable to antiviral therapy, and raising the possibility of a cure for herpes.

Dr Stacey Efstathiou, from Cambridge University, said that it was an "important" paper.

He said that an alternative strategy would be to use drugs to keep herpes virus in its latent state permanently, and prevent any flare-ups.

He added: "It's quite likely that over the next few years we will find a lot of viruses, such as HIV, have these small RNAs during latency."

Professor Roger Everett, a Medical Research Council virologist based in Glasgow, said that the research represented a step forward in a "long-standing problem" in the field.

The next step, he said would be to see what happened in an animal using a virus engineered to block production of these RNAs.

Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/7483832.stm

Published: 2008/07/02 23:05:22 GMT

© BBC MMVIII